Novellia wins 2026 Fierce Outsourcing Award for innovation in drug development

Novellia announced on April 14, 2026, that it has won the 2026 Fierce Outsourcing Award for Innovation in Drug Development, an honor presented by trade publication Fierce Pharma. The award highlights platforms and partnerships advancing how medicines are discovered, developed and delivered to patients.

The company said it was selected from a field of finalists that included established names in clinical research and drug development outsourcing. Novellia describes itself as a real-world data firm built entirely on information patients choose to share with medical researchers.

Pharmaceutical developers have long relied on real-world data to gauge how treatments perform beyond clinical trials. Novellia argues the current data ecosystem, dominated by third-party brokers piecing together records from insurers and hospital systems without direct patient input, costs the industry over $50 billion annually and omits critical patient-authorized information.

Its AI-powered platform is designed to address that gap by giving individuals a way to centralize their medical histories and contribute deidentified, anonymized data to research. According to Novellia, the tool helps patients with serious and complex conditions unify fragmented records from hospital systems, physicians' offices and laboratories across the U.S.

within about 30 seconds, creating harmonized datasets that are shared with research partners. The company says its customers include several of the top 10 pharmaceutical companies.

"The breakthroughs coming in medicine will be built on patient trust," said Shashi Shankar, Novellia’s co-founder and CEO, adding that the company focused on people with cancer, chronic and rare diseases to give researchers a fuller view of how illness unfolds over years.

Winners of the Fierce Outsourcing awards are slated to be celebrated during Fierce Biotech Week on Wednesday, May 13.